Connect to other sites within the UBM Medica Network
Low BMI Linked to Poorer Survival in Colorectal Cancer
A new study has found that in patients diagnosed with metastatic colorectal cancer, a low BMI could be a poor prognostic factor.
NK1 Antagonist Shows Promising Results for Emesis Prevention
Adding the oral NK1 antagonist aprepitant to an oxaliplatin-based chemotherapy regimen effectively reduced nausea and vomiting in colorectal cancer patients.
Priority Review for MM-398 in Advanced Pancreatic Cancer
The FDA has granted a priority review for MM-398 as a second-line treatment for metastatic pancreatic cancer after the drug demonstrated improved survival.
Citrus Fruit Consumption May Up Risk of Melanoma
Frequent consumers of citrus fruits were found to have an elevated risk of malignant melanoma.
TS Expression Could Guide Treatment in Nonsquamous NSCLC
The combination of pemetrexed/cisplatin was superior to gemcitabine/cisplatin in non-squamous NSCLC patients negative for the thymidylate synthase enzyme.
Marker Could Help Diagnose Early Pancreatic Cancer
Researchers have discovered a protein encoded by the GPC1 gene present on cancer exomes that may be used as a diagnostic tool to detect early pancreatic cancer.
Cervical Cancer Screening Declines, Fewer Lesions Detected
Detection of cervical lesions among young women has decreased since the introduction of HPV vaccines and guidelines calling for reduced cervical cancer screening.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
Adjuvant Chemo Ups Survival in High-Risk Localized Prostate Cancer
The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
By clicking Accept, you agree to become a member of the UBM Medica Community.